1区 · 医学
Article
作者: Cao, Wenyue ; Wang, Gaoxiang ; Zhang, Tongcun ; Huang, Liang ; Zhou, Xiaoxi ; Li, Chunrui ; Hu, Xuelian ; Cai, Haodong ; Yan, Dandan ; Wang, Na ; Lou, Yaoyao ; Zhang, Shangkun ; Zhang, Yicheng ; Cheng, Jiali ; Jiang, Lijun ; Chen, Liting ; Xiao, Yi ; Zheng, Miao ; Gu, Chaojiang ; Wang, Qiuxiang ; Cao, Yang ; Mao, Xia ; Wang, Di ; Zhou, Jianfeng
Relapse following chemeric antigen receptor (CAR) T-cell therapy can arise from progressive loss of the CAR T cells or from loss of the target antigen by tumor cells. Wang et al report that using a mix of CAR T cells targeting CD19 and CD22 reduces relapse with antigen-negative tumor cells. However, a lack of CAR T-cell persistence leads to increased relapse with antigen-positive cells.